Sangamo Therapeutics (SGMO.Q) Resumen de Acciones
Sangamo Therapeutics, Inc, una empresa de medicina genómica en fase clínica, se centra en traducir la ciencia en medicamentos que transformen la vida de los pacientes y las familias aquejados de enfermedades graves en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 2/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 1/6 |
| Dividendos | 0/6 |
SGMO.Q Community Fair Values
Create NarrativeSee what 39 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Sangamo Therapeutics, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$0.052 |
| Máximo en las últimas 52 semanas | US$0.77 |
| Mínimo de 52 semanas | US$0.03 |
| Beta | 1.29 |
| Cambio en 1 mes | -75.93% |
| Variación en 3 meses | -78.78% |
| Cambio de 1 año | -90.32% |
| Variación en 3 años | -96.12% |
| Variación en 5 años | -99.55% |
| Variación desde la OPV | -99.65% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 25
SGMO: Bankruptcy Restructuring Will Set Up Fabry-Focused Recovery Potential
The analyst price target for Sangamo Therapeutics has been cut from $10 to $5 as analysts factor in higher funding and partnership uncertainty related to completing the Fabry biologics license application and progressing the neurology pipeline. What’s in the News for Sangamo Therapeutics Sangamo Therapeutics filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on June 23, 2026, listing assets and liabilities each in the range of US$100 million to US$500 million, with Richards, Layton & Finger, P.A. and Cooley LLP as legal counsel, and MERU, LLC, Raymond James & Associates, Inc., and Kurtzman Carson Consultants LLC d/b/a Verita Global engaged as advisors and claims agent.
Actualización de narrativa • Jun 05
SGMO: Fabry Filing Progress Will Support Neurology Pipeline Despite Funding Uncertainty
Narrative Update: Sangamo Therapeutics Price Target Revision Analysts have cut their price target on Sangamo Therapeutics from $10 to $5. This reflects concerns about the uncertainty around securing a commercialization partner or sufficient funding to complete the Fabry biologics license application process and continue developing the neurology pipeline, even as the underlying regulatory and clinical thesis for isaralgagene civaparvovec remains in place.Recent updates
Actualización de narrativa • Jun 25
SGMO: Bankruptcy Restructuring Will Set Up Fabry-Focused Recovery Potential
The analyst price target for Sangamo Therapeutics has been cut from $10 to $5 as analysts factor in higher funding and partnership uncertainty related to completing the Fabry biologics license application and progressing the neurology pipeline. What’s in the News for Sangamo Therapeutics Sangamo Therapeutics filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on June 23, 2026, listing assets and liabilities each in the range of US$100 million to US$500 million, with Richards, Layton & Finger, P.A. and Cooley LLP as legal counsel, and MERU, LLC, Raymond James & Associates, Inc., and Kurtzman Carson Consultants LLC d/b/a Verita Global engaged as advisors and claims agent.Actualización de narrativa • Jun 05
SGMO: Fabry Filing Progress Will Support Neurology Pipeline Despite Funding Uncertainty
Narrative Update: Sangamo Therapeutics Price Target Revision Analysts have cut their price target on Sangamo Therapeutics from $10 to $5. This reflects concerns about the uncertainty around securing a commercialization partner or sufficient funding to complete the Fabry biologics license application process and continue developing the neurology pipeline, even as the underlying regulatory and clinical thesis for isaralgagene civaparvovec remains in place.Actualización de narrativa • Apr 20
SGMO: Fabry Filing Progress Will Offset Going Concern And Liquidity Fears
Analysts have updated their price target on Sangamo Therapeutics to reflect revised assumptions for the discount rate, revenue growth, profit margin and future P/E. The new fair value estimate remains at $1.00, in line with the prior $1.00 target.Actualización de narrativa • Apr 06
SGMO: Fabry Gene Therapy Filing And Diagnostic Will Drive Future Upside
Analysts have trimmed their price target on Sangamo Therapeutics from $1.25 to $1.00, citing updated assumptions for revenue growth, profit margins and future P/E that have reset expectations for the stock. What's in the News Sangamo reported unaudited impairment charges on long lived assets of US$13,235,000 for the fourth quarter ended December 31, 2025, which affects reported earnings quality for that period (Key Developments).Actualización de narrativa • Mar 22
SGMO: Fabry Gene Therapy Filing And Kidney Endpoint Will Drive Upside
Analysts have adjusted their price target on Sangamo Therapeutics to $1.25, with the change based on updated views on discount rate, revenue growth, profit margin, and future P/E assumptions, even though the fair value estimate itself remains $1.25. What's in the News Sangamo started a rolling submission of a Biologics License Application to the FDA for isaralgagene civaparvovec (ST-920), an investigational one time gene therapy for adults with Fabry disease, and has submitted the preclinical and clinical modules for review (Key Developments).Actualización de narrativa • Mar 08
SGMO: Accelerated Approval Pathway On Kidney Data Will Drive Bullish Upside
Analysts have set their price target for Sangamo Therapeutics at $1.25, based on updated assumptions for discount rate, revenue growth, profit margin, and future P/E, while the fair value estimate remains unchanged at $1.25. What's in the News Sangamo reported detailed data from the registrational Phase 1/2 STAAR study of its gene therapy candidate isaralgagene civaparvovec (ST 920) for Fabry disease.Actualización de narrativa • Feb 22
SGMO: Accelerated Approval On Kidney Function Data Will Drive Bullish Thesis
Analysts have maintained their average price target for Sangamo Therapeutics at $1.25. This reflects minor adjustments to their models, including slightly different assumptions for discount rate, revenue growth, profit margin, and forward P/E, rather than a change in their overall view.Actualización de narrativa • Feb 07
SGMO: Accelerated Approval Using EGFR Slope Will Support Bullish Outlook
Analysts have nudged their fair value estimate for Sangamo Therapeutics higher to $1.25 from $1.00, citing updated assumptions around revenue growth, profit margins, discount rates and a higher future P/E multiple. What's in the News Sangamo Therapeutics completed a follow on equity offering totaling approximately US$24.8 million, issuing 35,190,292 shares of common stock at US$0.4719 per share and 17,787,033 pre funded warrants at US$0.4619 per warrant (Key Developments).Artículo de análisis • Feb 03
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have had a really impressive month, gaining 29% after a shaky period...
Actualización de narrativa • Jan 23
SGMO: Accelerated Approval Pathway Will Drive Upside Despite Downgrade Through 2026
Narrative Update Analysts have cut their price target on Sangamo Therapeutics from US$5 to US$1, citing the recent downgrade to Equal Weight and a wait for more clarity on a potential Fabry deal, despite the FDA reaffirming an accelerated approval path and the company extending its cash runway into Q1 2026. Analyst Commentary Recent research paints a mixed picture for Sangamo Therapeutics, with the lower price target and rating downgrade balanced against some supportive clinical and balance sheet signals.Actualización de narrativa • Jan 09
SGMO: Accelerated Approval Path Using EGFR Slope Will Drive Future Upside
Analysts have trimmed their 12 month price target on Sangamo Therapeutics to US$1 from US$5, citing a wait and see stance on Fabry deal clarity and the current cash runway into Q1 2026, despite the reaffirmed accelerated approval path using eGFR slope. Analyst Commentary Bearish analysts are signaling a more cautious stance on Sangamo Therapeutics after the recent Q3 update, with the sharp cut in the 12 month price target standing out as a key marker of reduced confidence.Actualización de narrativa • Dec 25
SGMO: Accelerated Approval Pathway And Extended Runway Will Support Upside Through 2026
Analysts have modestly reduced their price target on Sangamo Therapeutics to $1 from $5, citing a more cautious stance as they await greater clarity on potential Fabry partnership developments, despite the extended cash runway and reaffirmed accelerated approval pathway. Analyst Commentary Analysts note that the downgrade and lower price target reflect a shift toward a more balanced risk reward profile, with recent catalysts prompting both supportive and cautious views on Sangamo Therapeutics.Actualización de narrativa • Dec 11
SGMO: Accelerated Approval Pathway Is Expected To Drive Upside Through 2026
Analysts have lowered their price target on Sangamo Therapeutics from $5.00 to $1.00 per share, citing a more cautious stance as they await greater clarity on a potential Fabry partnership, despite an extended cash runway and a reaffirmed accelerated approval path. Analyst Commentary Analysts are reassessing Sangamo Therapeutics with a more balanced view, emphasizing both the company’s de-risked regulatory path and the uncertainties that could weigh on execution and valuation.Actualización de narrativa • Nov 27
SGMO: FDA Accelerated Pathway Will Extend Bullish Momentum Into 2026
Analysts have lowered Sangamo Therapeutics’ price target from $5 to $1, citing uncertainty around future partnership deals. This is despite recent regulatory updates and an extended cash runway.Artículo de análisis • Nov 23
Revenues Working Against Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Following 33% Dive
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have had a horrible month, losing 33% after a relatively good period...Actualización de narrativa • Nov 08
SGMO: FDA Approval Path Will Drive Bullish Outlook Into 2026
Analysts have lowered their price target for Sangamo Therapeutics from $5 to $1. They cited a cautious outlook, pending greater clarity on a Fabry collaboration and updated guidance following the company's latest quarterly report.Artículo de análisis • Oct 07
There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 28% Share Price Rise
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have continued their recent momentum with a 28% gain in the last...Artículo de análisis • Sep 23
Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Actualización de narrativa • Sep 21
FDA Approval In 2026 Will Extend Fabry Gene Therapy Prospects
The sharp increase in Sangamo Therapeutics' consensus analyst price target is primarily driven by a significantly higher future P/E expectation, indicating greater anticipated earnings growth or improved sentiment, with the fair value rising from $2.62 to $4.10. What's in the News CFO Prathyusha Duraibabu resigned, effective October 1, to join a private AI company; no disagreements cited in her departure.Actualización de narrativa • Sep 06
FDA Approval In 2026 Will Extend Fabry Gene Therapy Prospects
Sangamo Therapeutics' fair value has been revised downward, primarily reflecting meaningful declines in both its forward P/E multiple and net profit margin, resulting in a lower consensus price target of $2.62. What's in the News Sangamo presented detailed data from the registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), its investigational gene therapy for adults with Fabry disease, showing a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year in all patients followed at least 12 months.Artículo de análisis • Jul 24
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Those holding Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares would be relieved that the share price has rebounded...
Nueva narrativa • Apr 01
Neurology IND And Fabry Agreements Will Transform Treatment
Strategic partnerships and collaborations position Sangamo as a key player, enhancing revenue potential through non-dilutive capital and licensing agreements.Artículo de análisis • Mar 04
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
To the annoyance of some shareholders, Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares are down a considerable 25% in...Artículo de análisis • Dec 08
Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30%
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have retraced a considerable 30% in the last month, reversing a fair...Artículo de análisis • Nov 20
Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders will have a reason to smile today, with the analysts making...Artículo de análisis • Oct 23
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have continued their recent momentum with a 26% gain in the last...Seeking Alpha • Oct 21
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?
Summary Sangamo Therapeutics, Inc.'s stock surged after positive updates on two lead assets, giro-vec and STAC-BBB, with potential for significant milestone payments and partnerships. The upcoming isa-vec deal could be transformative, potentially securing Sangamo's financial stability and pushing its valuation towards $1 billion. Despite recent gains, high volatility and financial risks make SGMO a speculative investment, suitable only for risk-tolerant investors. Key risks include potential setbacks in giro-vec and isa-vec developments, which could impact Sangamo's cash flow and overall valuation. Read the full article on Seeking AlphaArtículo de análisis • Aug 03
There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders would be excited to see that the share price has had a great...Seeking Alpha • Jul 23
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Summary Sangamo Therapeutics, Inc. is almost out of cash, and as such, at risk of bankruptcy. Therefore, investing in this company is not a good idea for most investors. 3 of its assets have updates coming over the next 1–6 months that could realistically bring in a combination of ~$1B of cash & milestones over the next 12–18 months. Due to its history of burning cash and not being able to get a drug approved yet, Sangamo Therapeutics's stock price closed Monday, 07/22/24 at $0.395/s or a valuation of ~$82M. Below, I will discuss why I think the company is going to make it and possibly deliver 5-10x over the next 6–12 months. Read the full article on Seeking AlphaArtículo de análisis • Jun 19
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop
Unfortunately for some shareholders, the Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) share price has dived 35% in the...Artículo de análisis • May 29
We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package
Key Insights Sangamo Therapeutics' Annual General Meeting to take place on 4th of June CEO Sandy Macrae's total...Artículo de análisis • May 14
This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year
Shareholders in Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) may be thrilled to learn that the analysts have just...Artículo de análisis • Mar 23
Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have retraced a considerable 36% in the last month, reversing a fair...Artículo de análisis • Mar 16
Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%
Today is shaping up negative for Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders, with the analysts delivering...Rentabilidad de los accionistas
| SGMO.Q | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -69.9% | 6.1% | 0.3% |
| 1Y | -90.3% | 40.6% | 19.9% |
Rentabilidad vs. Industria: Los resultados de SGMO.Q fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 40.6% el año pasado.
Rentabilidad vs. Mercado: SGMO.Q obtuvo unos resultados inferiores a los del mercado US, que fueron del 19.9% el año pasado.
Volatilidad de los precios
| SGMO.Q volatility | |
|---|---|
| SGMO.Q Average Weekly Movement | 33.2% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: El precio de las acciones de SGMO.Q ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de SGMO.Q ha aumentado de 21% a 33% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1995 | 142 | Sandy Macrae | www.sangamo.com |
Sangamo Therapeutics, Inc, una empresa de medicina genómica en fase clínica, se centra en convertir la ciencia en medicamentos que transformen la vida de los pacientes y las familias afectados por enfermedades graves en Estados Unidos. Los productos candidatos de la empresa en fase clínica son ST-920, un producto candidato a terapia génica, que se encuentra en estudio clínico de fase 1/2 para el tratamiento de la enfermedad de Fabry; neuropatía de fibras pequeñas para el dolor neuropático crónico, y enfermedad priónica; ensayo clínico de fase 1/2 para evaluar la seguridad y tolerabilidad de la terapia celular modificada genéticamente TX200, en fase de investigación, en pacientes sometidos a un trasplante de riñón SB-525, un candidato a producto de terapia génica, que se encuentra en ensayo clínico de fase 3 para el tratamiento de la hemofilia A de moderadamente grave a grave; giroctocogene fitelparvovec, un estudio de fase 3 para evaluar la eficacia clínica y la seguridad de la terapia génica giroctocogene fitelparvovec en varones adultos con hemofilia A moderadamente grave o grave.
Resumen de fundamentos de Sangamo Therapeutics, Inc.
| Estadísticas fundamentales de SGMO.Q | |
|---|---|
| Capitalización bursátil | US$18.64m |
| Beneficios(TTM) | -US$123.33m |
| Ingresos (TTM) | US$34.56m |
0.6x
Ratio precio-ventas (PS)-0.2x
Ratio precio-beneficio (PE)¿Está SGMO.Q sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de SGMO.Q | |
|---|---|
| Ingresos | US$34.56m |
| Coste de los ingresos | US$113.23m |
| Beneficio bruto | -US$78.68m |
| Otros gastos | US$44.65m |
| Beneficios | -US$123.33m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.30 |
| Margen bruto | -227.67% |
| Margen de beneficio neto | -356.89% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado SGMO.Q a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/29 06:30 |
| Precio de las acciones al final del día | 2026/06/29 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Sangamo Therapeutics, Inc. está cubierta por 16 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Gregory Harrison | BofA Global Research |
| Douglas Buchanan | Brean Capital Historical (Janney Montgomery) |
| John Newman | Citizens JMP Securities, LLC |